Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8195106 | 0.85 | LMNA (0.55) | LMNAMEN1KMT2AABCC4PKM | |
| SCHEMBL3696586 | 0.85 | LMNA (0.64) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL20240664 | 0.84 | LMNA (0.39) | LMNAMEN1KMT2AABCC4PKM | |
| SCHEMBL20240766 | 0.84 | GSK3B (0.47) | LMNAMEN1KMT2AABCC4PKM | |
| SCHEMBL21815683 | 0.82 | HSD17B10 (0.42) | LMNAMEN1KMT2AABCC4PKM | |
| SCHEMBL3693908 | 0.82 | LMNA (0.52) | LMNAMEN1KMT2ACYP2C9TSHR | |
| SCHEMBL3702513 | 0.81 | LMNA (0.50) | LMNAMEN1KMT2ACYP2C9TSHR | |
| SCHEMBL20257884 | 0.81 | LMNA (0.36) | LMNAMEN1KMT2AABCC4PKM | |
| SCHEMBL27952590 | 0.80 | LMNA (0.50) | LMNAMEN1KMT2AABCC4PKM | |
| SCHEMBL3695215 | 0.80 | LMNA (0.40) | LMNAMEN1KMT2AABCC4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569484-B2 | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| CN-102448962-A | Heterocyclic urea derivatives and methods of use thereof | ASTRAZENECA AB | 2012-05-09 | — | — | CN | disclosed |
| WO-2010136817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | WO | disclosed |
| US-3963736-A | Preparation of 1-(lower alkyl)-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acids | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122817-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | LMNA 2498/4885MEN1 1874/4885KMT2A 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.